Prognostic Value of the Nutritional Status in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoints Inhibitors

C. Le Bris,P. Boudou-Rouquette,A. Jouinot,J. Arrondeau,S. De Percin,G. Ulmann,C. Tlemsani,I. Gataa,J. Chapron,F. Giraud,A. Lupo,D. Damotte,E. Fabre,J.-P. Durand, J. Alexandre,M. Wislez,L. Cynober,F. Goldwasser

Clinical nutrition ESPEN（2020）

引用 0|浏览39

暂无评分

摘要

Rationale: Malnutrition is associated with immune dysfunction and inflammatory processes. Immune checkpoint inhibitors (ICI) provide an immense breakthrough in cancer therapeutics, especially for lung cancer. However, a significant proportion of patients (pts) experienced disease progression shortly after starting single-agent ICI treatment even after biomarker selection, such as programmed cell death-ligand 1(PD-L1). We studied the relationship between nutritional biomarkers and benefit from ICI among pts with mNSCLC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要